The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Osimertinib, a third-generation EGFR TKI, offers survival benefits for metastatic NSCLC.
• Concerns exist regarding osimertinib's cardiotoxicity in real-world clinical practice.

Purpose of the Study:

• To investigate the incidence, risk factors, and reversibility of osimertinib-related cardiotoxicity.
• To assess real-world cardiotoxicity data for this targeted therapy.

Main Methods:

• Analysis of 1126 NSCLC patients treated with osimertinib (May 2016-April 2023).
• Cardiotoxicity defined as cardiac dysfunction, arrhythmia, or cardiac death.
• Follow-up duration of 20.6 months.

Main Results:

• Osimertinib-related cardiotoxicity incidence was 4.7%.
• Independent risk factors included advanced age, heart failure history, atrial fibrillation, and low baseline left ventricular strain.
• Osimertinib-related cardiac dysfunction recovery rate was 82.4%.

Conclusions:

• Real-world cardiotoxicity incidence (4.7%) is higher than previously reported.
• Vigilant cardiac monitoring is essential for patients on long-term osimertinib, especially those with identified risk factors.
• Early detection and management of cardiotoxicity are crucial for improving patient outcomes.